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Interest in minimizing corticosteroid exposure is
widespread given the potential associated morbidity. This
morbidity may be greater in children where the hope for a
lifetime of transplant benefit has been historically linked to
the risks of long-term corticosteroids. Corticosteroids also
compromise growth, a unique concern in children. Con-
trasting the potential benefit of less steroid exposure is
the potential risk for increased rates of rejection and graft
loss. Balancing all risks and benefits is critical.
In January 2001, the CCPT Study Group initiated a multi-
center randomized double-blind placebo controlled study
of steroid withdrawal at 6 months after transplantation.
Positing more intensive immunosuppression would de-
crease early rejection and permit subsequent steroid with-
drawal, the protocol combined Basiliximab induction, with
cyclosporine or tacrolimus, sirolimus and steroids. At 6
months, rejection free subjects and those without another
event resulting in discontinuation underwent a protocol
biopsy. Subjects free from histologic evidence of rejection
were randomized to a 6 month tapered steroid withdrawal
or continued steroid maintenance. The trial was terminated
in August 2004 due to 6.9% of subjects enrolled develop-
ing PTLD (1). The treatment assignments were unblinded,
and a follow-up assessment initiated.
In this issue of AJT , Benfield et al. report the outcomes
of the study (2). At termination, 274 of the anticipated 600
subjects were enrolled. Of the 132 that were randomized,
73 were assigned to withdrawal and 59 to maintenance.
This represents the first peer reviewed controlled trial of
steroid withdrawal in pediatric recipients. Despite enthu-
siasm for this report, one must recognize the challenges
interpreting outcomes from studies having such a signifi-
cant prerandomization selection, as well as any study ter-
minated early. More limited enrollment compromises sta-
tistical power, impacting the potential for subgroup analy-
sis and conclusions, especially for infrequent events. Both
statistical and methodological errors may be introduced.
Randomization may not have achieved appropriate balance
for all important risk factors. Despite an overall 1:1 random-
ization design, there is a substantial imbalance in the arms
due to block randomization. While the groups appear rel-
atively comparable, the smaller sample size compromises
the power of randomization. Additionally, unblinding intro-
duces potential for subsequent reporting bias, particularly
for subjective data.
Regarding the primary endpoint, withdrawal subjects had
a greater standardized height velocity. The improvement
observed was modest; at 18 months there was no dif-
ference in height z-score. There is baseline data on only
59 of 73 withdrawal subjects and 51 of 59 maintenance
subjects. At 18 months, there was data on 35 and 28, re-
spectively. This relatively low rate of reporting raises the
potential for unknown, and potentially non-random, selec-
tion bias. It is interesting that the median age of withdrawal
group (11.9 years) was lower than the maintenance group
(13.5 years). Although age was a covariate in this analy-
sis, it is unclear how pubertal status was accounted for.
Given prepurbertal status is associated with better catch
up growth, this difference may contribute to the observa-
tion. Conversely, the benefit of withdrawal may be less
than expected given the withdrawal group was not steroid
free until 12 months posttransplant. The impact may also
have been attenuated by the relatively low steroid dose
in the maintenance arm. Will this trend in height veloc-
ity continue and translate into clinically significant differ-
ence? Height data is only presented from 6 to 18 months
while the study appears structured to provide 36 months
of follow-up for other endpoints.
In evaluating other potential benefits of withdrawal, there
was a lower Cushingoid assessment score, suggesting in-
vestigators could detect changes attributable to steroids.
If some scoring was completed after unblinding, there is
potential for bias. With respect to more objective data,
there were no differences in lipid profiles or hypertension,
potentially reflecting a Type II error, a lower risk associ-
ated with the dose of maintenance steroids, or attenua-
tion of the benefit of withdrawal by 6 months of steroids
treatment.
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Regardless of the certainty or magnitude in this trial, there
is enough evidence to believe that avoidance of steroids is
associated with benefits. It is the potential balance of risk
that causes concern. The authors report no differences in
rejection rates or graft function. At 3 years, allograft survival
was greater in the withdrawal group compared to the main-
tenance group (98.6% vs. 84.5%, respectively). Of note
there were more deaths in the maintenance group, with
four of the five plausibly linked to over immunosuppres-
sion associated with the protocol. Again, the results need
to be interpreted with caution. The temptation to believe
withdrawal is directly responsible for the increased graft
survival, or conversely steroid therapy is worse, should be
resisted. A reasonable interpretation might be that steroid
withdrawal, in the setting of this specific protocol, was
not associated with a large increase in risk of rejection or
graft failure, acknowledging this trial was not structured to
demonstrate noninferiority and the follow-up is 3 years.
Excellent results have been demonstrated in single center
reports (3). Two additional multicenter randomized trials
evaluating early steroid withdrawal and avoidance have re-
cently completed (4,5) and hopefully will provide additional
insight. Long-term follow up from all studies is essential.
This study represents a monumental undertaking started
nearly a decade ago. Such large scale studies are vital if
we are to improve care. The results must be viewed in
context of the protocol utilized, which the authors clearly do
not recommend. The study provides rationale to continue
trials seeking to minimize steroid exposure, and frames
many issues of study design in this challenging population.
To achieve the right balance we must accurately determine
the magnitude of all the risks and benefits, in both the short
and long term.
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